kabutan

Fuso Pharmaceutical Industries,Ltd., First Half Ordinary Profit Revised Upward to an Unexpected 91% Increase

Fri Nov 1, 2024 4:00 pm JST Revision

4538 Fuso Pharmaceutical Industries,Ltd. 【J-GAAP】

Guidance Update Report

Fuso Pharmaceutical Industries,Ltd. <4538> [TSE-P] announced a performance revision after the market closed on November 1st (16:00). The ordinary profit (non-consolidated) for the cumulative second quarter of the fiscal year ending March 2025 (April to September) has been revised upward by 2.1 times, from the previous forecast of 1 billion yen to 2.1 billion yen (compared to 1.09 billion yen in the same period of the previous year), turning to a 91.3% increase in the ordinary profit outlook.

Furthermore, the full-year ordinary profit forecast remains unchanged from the estimate of 2.3 billion yen(compared to 1.86 billion yen in the previous period).

Kabutan News

Guidance Update

First Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 Prev 28,200 1,300 1,000 700 81.9 40 May 10, 2024 J-GAAP
Apr - Sep, 2024 New 29,700 2,400 2,100 1,500 175.6 40 Nov 1, 2024 J-GAAP
Revision Rate +5.3% +84.6% +110.0% +114.3% +114.3%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2023 27,424 1,099 1,098 717 82.2 35 Nov 10, 2023 J-GAAP
Apr - Sep, 2024 Guidance 29,700 2,400 2,100 1,500 175.6 40 Nov 1, 2024 J-GAAP
YoY +8.3% +118.4% +91.3% +109.2% +113.6%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 51,015 2,206 2,215 1,605 183.1 70 May 10, 2023 J-GAAP
Mar, 2024 55,407 1,964 1,868 1,377 160.0 70 May 10, 2024 J-GAAP
Mar, 2025 Guidance 57,000 2,600 2,300 1,700 199.0 80 May 10, 2024 J-GAAP
YoY +2.9% +32.4% +23.1% +23.5% +24.4%

Related Articles